Cambrios lands $14.5M for electronic display components
Cambrios, maker of conductive films used in electronic displays and monitors, has brought in $14.5 million in a fourth round of venture capital. Based in Sunnyvale, Calif., the company is backed by ARCH Venture Partners, Alexandria Real Estate Equities, Alloy Ventures, Altitude Life Science Ventures, Avalon Ventures, Harris & Harris Group, Headland Ventures, In-Q-Tel, Kidron, Lux Capital, Mitsubishi UFJ Capital, Oxford Bioscience Partners, Presidio Ventures, Sumitomo, Chisso and Nissha Printing.
Life-science briefing: Friday, March 14, 2008
TODAY’S HEADLINES
Cantimer takes in $2M for dehydration diagnostics (VentureWire)
Recodagen launches, takes aim at cancer (release)
Juniper Diagnostics spins out of ChemSensing (VentureWire)
Cantimer takes in $2M for dehydration diagnostics –The mystery of Menlo Park, Calif.-based Cantimer has resolved a bit. We wrote about this stealthy company back in December and reached the conclusion that the company was developing a particular type of nanosensor intended to identify water levels in human tissue.
Now VentureWire reports that Cantimer is doing… Continue Reading
Life sciences briefing: Thursday, Jan. 3, 2008
TODAY’S HEADLINES:
Gelesis draws in $16M for obesity treatments (release)
Tempo Pharma raises $8B for nanoparticle drugs (release)
Calistoga Pharma receives additional $5M for cancer and inflammation drugs (release)
Montreux Equity Partners closes $250M life-sciences fund (release)
MTS Health Partners names Andrew Weisenfeld, Mark Epstein managing directors (release)
T2 Biosystems names John McDonough as CEO (release)
Gelesis draws in $16M for obesity treatments — Gelesis, a stealthy Boston company working on “novel” obesity treatments, raised $16 million in a first funding round…. Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech focused on tweaking existing protein-based drugs to improve their properties, raised $30 million in a second round of financing. Investors included MPM Capital, OVP Venture Partners, Amgen Ventures, ARCH Venture… Continue Reading
Antibiotic maker BioRelix gets $26M
BioRelix, a New Haven, Conn., developer of new antibiotics, raised $25.75 million in a first funding round, VentureWire reports (subscription required). The round included New Leaf Venture Partners, Aisling Capital, CHL Medical Partners, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.
BioRelix is developing antibiotics that target what the company says are common stretches of bacterial RNA that control many functions essential for bacterial survival. The funding should allow the company to push… Continue Reading